{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:47Z","timestamp":1790874947574,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2008,7,1]]},"DOI":"10.4140\/tcp.n.2008.531","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:11:27Z","timestamp":1294884687000},"page":"531-537","source":"Crossref","is-referenced-by-count":3,"title":["&lt;b&gt;Strontium Ranelate for the Management of Osteoporosis&lt;\/b&gt;"],"prefix":"10.4140","volume":"23","author":[{"given":"Sum","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zouzias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"NIH Consensus Development Panel on Osteroporosis Prevention, Diagnosis and Therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","year":"1993","journal-title":"Am J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bone.2005.07.029","article-title":"Strontium ranelate: a physiological approach for optimizing bone formation and resorption","volume":"38","author":"P Marie","year":"2006","journal-title":"Bone"},{"key":"4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","article-title":"The components of excess mortality after hip fracture","volume":"32","author":"J Kans","year":"2003","journal-title":"Bone"},{"key":"5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"J Cauley","year":"2000","journal-title":"Osteoporos Int"},{"key":"6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","article-title":"An estimate of the worldwide prevalence, mortality and disability associated with hip fracture","volume":"15","author":"O Johnell","year":"2004","journal-title":"Osteroporos Int"},{"key":"7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.blo.0000200241.14684.4e","article-title":"Mineral changes in osteoporosis: a review","volume":"443","author":"D Faibish","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(02)08706-8","article-title":"Pathogenesis of bone fragility in women and men","volume":"359","author":"E Seeman","year":"2002","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","article-title":"Summary of meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"A Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"B Riggs","year":"2005","journal-title":"J Bone Miner Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"P Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"12","unstructured":"12. Summary of product characteristics. Protelos (strontium ranelate). Available at http:\/\/www.servier.com\/Pro\/Osteoporosis\/Protelos\/Protelos.aspx?id=367. Updated November 2007. Accessed May 7, 2008. <a target=\"_blank\" href='http:\/\/www.servier.com\/Pro\/Osteoporosis\/Protelos\/Protelos.aspx?id=367'>http:\/\/www.servier.com\/Pro\/Osteoporosis\/Protelos\/Protelos.aspx?id=367<\/a>"},{"key":"13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1359\/jbmr.2003.18.6.1082","article-title":"S 12911-2 Inhibits osteoclastic bone resorption in vitro","volume":"18","author":"N Takahashi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1742-1241.2006.01249.x","article-title":"Strontium ranelate in the prevention of osteoporotic fractures","volume":"61","author":"J Reginster","year":"2007","journal-title":"Int J Clin Pract"},{"key":"15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(96)00080-4","article-title":"The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro","volume":"18","author":"E Canalis","year":"1996","journal-title":"Bone"},{"key":"16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S8756-3282(01)00484-7","article-title":"Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis)","volume":"29","author":"J Fuehler","year":"2001","journal-title":"Bone"},{"key":"17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00198-002-1347-2","article-title":"The mineralization of bone tissue: a forgotten dimension in osteoporosis research","volume":"14","author":"G Boivin","year":"2003","journal-title":"Osteoporos Int"},{"key":"18","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1359\/jbmr.040906","article-title":"Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats","volume":"19","author":"P Ammann","year":"2004","journal-title":"J Bone Miner Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s001980200129","article-title":"Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial","volume":"13","author":"J Reginster","year":"2002","journal-title":"Osteoporos Int"},{"key":"20","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1210\/jc.87.5.2060","article-title":"Strontium ranelate: dosedependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial","volume":"87","author":"P Meunier","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"21","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study","volume":"90","author":"J Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1359\/JBMR.040316","article-title":"Osteoporosis and the global competition for health care resources","volume":"19","author":"L Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.blo.0000200247.27253.e9","article-title":"Strontium ranelate. The first dual acting treatment for postmenopausal osteoporosis","volume":"443","author":"N Burlet","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"24","first-page":"54","article-title":"Beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI Study)","volume":"16","author":"P Marquis","year":"2005","journal-title":"Osteoporos Int"},{"key":"25","unstructured":"25. Clinical trial: teriparatide and strontium ranelate head-to-head comparison trial. Available at http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00239629?order=1. Accessed May 21, 2007. <a target=\"_blank\" href='http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00239629?order=1'>http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00239629?order=1<\/a>"},{"key":"26","volume-title":"Pharmacotherapy: A Pathophysiologic Approach, 6th ed","author":"M O'Connell","year":"1999"},{"key":"27","unstructured":"27. Strontium ranelate chemical structure. Available at http:\/\/www.chemblink.com\/products\/135459-87-9.htm. Accessed May 7, 2008. <a target=\"_blank\" href='http:\/\/www.chemblink.com\/products\/135459-87-9.htm'>http:\/\/www.chemblink.com\/products\/135459-87-9.htm<\/a>"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:05:55Z","timestamp":1637132755000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2008\/00000023\/00000007\/art00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7,1]]}},"alternative-id":["11RX2355824851L5"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2008.531","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}